By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Mersana Therapeutics, Inc. 

840 Memorial Drive
2nd Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-0020 Fax: n/a


SEARCH JOBS

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.

Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.

YEAR FOUNDED:

2015

LEADERSHIP:

CEO: Anna Protopapas

Chief Medical Officer: Donal A. Bergstrom

Chief Business Officer: Eva M. Jack

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@mersana.com
Ownership: Private

Web Site: Mersana
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Booming Mersana Nabs Another $33 Million for a Total Take of $120 Million+ 6/16/2016 6:40:48 AM
Takeda (TKPYY) Wagers $1 Billion+ More on Mersana Therapeutics' Antibody Program 2/3/2016 7:50:49 AM
Mersana Therapeutics' Lead Immunoconjugate Continues To Demonstrate Complete Tumor Regressions In Multiple HER2-Expressing Breast Cancer Tumor Models 12/14/2015 7:42:20 AM
Mersana Therapeutics To Present Poster At The 2015 San Antonio Breast Cancer Symposium 12/1/2015 10:07:07 AM
Mersana Therapeutics To Present At World ADC San Diego 10/16/2015 8:11:32 AM
Mersana Therapeutics' Lead Fleximer Immunoconjugate Demonstrates Potent Activity In Low HER2-Expressing Tumor Models 4/17/2015 2:51:12 PM
Mersana Therapeutics To Present Late-Breaking Poster At American Association for Cancer Research Annual Meeting 2015 4/15/2015 7:16:31 AM
Mersana Therapeutics Nabs $35 Million And A New CEO 3/2/2015 10:44:14 AM
Mersana Therapeutics, Inc., Takeda Pharmaceutical Co. Ltd. (TKPYY) Expand Antibody-Drug Pact By $300 Million 1/12/2015 6:17:41 AM
Mersana Therapeutics, Inc. And Takeda Pharmaceutical Co. Ltd. (TKPYY) Enter Commercial License Agreement For Novel Fleximer® Antibody-Drug Conjugate 10/27/2014 10:47:56 AM
12345
//-->